Total Payments
$415,828
2024 Payments
$114,991
Companies
25
Transactions
746
Medicare Patients
1,435
Medicare Billing
$223,181
Payment Breakdown by Category
Other$312,423 (75.1%)
Research$38,034 (9.1%)
Travel$26,191 (6.3%)
Consulting$23,708 (5.7%)
Food & Beverage$15,461 (3.7%)
Education$11.78 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $305,400 | 98 | 73.4% |
| Unspecified | $38,034 | 9 | 9.1% |
| Travel and Lodging | $26,191 | 120 | 6.3% |
| Consulting Fee | $23,708 | 10 | 5.7% |
| Food and Beverage | $15,461 | 505 | 3.7% |
| Honoraria | $7,023 | 2 | 1.7% |
| Education | $11.78 | 2 | 0.0% |
Payments by Type
General
$377,795
737 transactions
Research
$38,034
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $181,578 | 323 | $0 (2024) |
| ABBVIE INC. | $102,682 | 202 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $45,959 | 35 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $33,186 | 4 | $0 (2021) |
| Madrigal Pharmaceuticals | $19,184 | 23 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $13,254 | 37 | $0 (2018) |
| Echosens North America, Inc. | $5,120 | 3 | $0 (2024) |
| Eli Lilly and Company | $5,020 | 20 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $4,188 | 7 | $0 (2020) |
| Allergan Inc. | $2,667 | 12 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $114,991 | 164 | Ipsen Biopharmaceuticals, Inc ($45,924) |
| 2023 | $30,616 | 83 | ABBVIE INC. ($16,562) |
| 2022 | $21,991 | 68 | ABBVIE INC. ($12,354) |
| 2021 | $27,522 | 66 | Gilead Sciences, Inc. ($15,501) |
| 2020 | $16,839 | 50 | Gilead Sciences, Inc. ($10,471) |
| 2019 | $77,538 | 96 | E.R. Squibb & Sons, L.L.C. ($31,713) |
| 2018 | $54,380 | 100 | Gilead Sciences, Inc. ($35,857) |
| 2017 | $71,952 | 119 | Gilead Sciences Inc ($36,944) |
All Payment Transactions
746 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $9.00 | General |
| Category: VIROLOGY | ||||||
| 12/17/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,410.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/17/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: Gastroenterology | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $10.03 | General |
| 12/10/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,930.00 | General |
| Category: INFLAM | ||||||
| 12/10/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Rare Disease | ||||||
| 12/10/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $12.57 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Travel and Lodging | In-kind items and services | $955.70 | General |
| Category: INFLAM | ||||||
| 12/03/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $119.66 | General |
| Category: INFLAM | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: LIVER DISEASE | ||||||
| 12/02/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.72 | General |
| 12/02/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $8.48 | General |
| 11/27/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Honoraria | Cash or cash equivalent | $2,523.00 | General |
| Category: Rare Disease | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $50.35 | General |
| Category: Gastroenterology | ||||||
| 11/21/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/21/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $24.92 | General |
| Category: LIVER DISEASE | ||||||
| 11/21/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: Rare Disease | ||||||
| 11/18/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $29.08 | General |
| Category: VIROLOGY | ||||||
| 11/16/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Rare Disease | ||||||
| 11/15/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $2.99 | General |
| Category: VIROLOGY | ||||||
| 11/13/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/13/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.84 | General |
| Category: Gastroenterology | ||||||
| 11/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $11.50 | General |
| 11/08/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $5.60 | General |
| Category: VIROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 PEG-FGF21 IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND STAGE 3 LIVER FIBROSIS | E.R. Squibb & Sons, L.L.C. | $19,975 | 1 |
| A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 PEG-FGF21 IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND COMPENSATED LIVER CIRRHOSIS | E.R. Squibb & Sons, L.L.C. | $11,738 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $4,557 | 4 |
| A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF21) IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 LIVER FIBROSIS | E.R. Squibb & Sons, L.L.C. | $1,002 | 1 |
| A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF21) IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND COMPENSATED LIVER CIRRHOSIS | E.R. Squibb & Sons, L.L.C. | $471.20 | 1 |
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $291.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 363 | 514 | $197,138 | $58,696 |
| 2022 | 8 | 380 | 520 | $134,894 | $54,925 |
| 2021 | 7 | 397 | 599 | $137,509 | $65,024 |
| 2020 | 4 | 295 | 424 | $102,065 | $44,535 |
Total Patients
1,435
Total Services
2,057
Medicare Billing
$223,181
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 120 | 249 | $109,660 | $34,380 | 31.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 51 | 51 | $27,540 | $8,703 | 31.6% |
| 76981 | Ultrasound scan of organ tissue for measuring elasticity | Office | 2023 | 77 | 82 | $21,320 | $6,890 | 32.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 75 | 92 | $26,588 | $6,063 | 22.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 29 | 29 | $10,875 | $2,587 | 23.8% |
| 91200 | Measurement of liver stiffness | Facility | 2023 | 11 | 11 | $1,155 | $74.16 | 6.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 121 | 221 | $63,272 | $30,911 | 48.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 64 | 64 | $21,840 | $10,584 | 48.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 52 | 68 | $18,433 | $5,043 | 27.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 32 | 36 | $8,252 | $2,287 | 27.7% |
| 76981 | Ultrasound scan of organ tissue for measuring elasticity | Office | 2022 | 19 | 20 | $5,520 | $1,729 | 31.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 14 | 14 | $5,232 | $1,325 | 25.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 16 | 16 | $4,147 | $1,142 | 27.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 17 | 18 | $4,301 | $1,040 | 24.2% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 32 | 36 | $3,600 | $784.19 | 21.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 13 | 27 | $297.00 | $80.34 | 27.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 163 | 318 | $77,466 | $41,790 | 53.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 69 | 69 | $21,290 | $11,620 | 54.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 63 | 87 | $20,441 | $6,753 | 33.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 23 | 23 | $8,104 | $2,291 | 28.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 13 | 18 | $4,248 | $1,422 | 33.5% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2021 | 41 | 42 | $4,200 | $959.04 | 22.8% |
| 91200 | Measuring the stiffness in the liver via elastography | Facility | 2021 | 11 | 11 | $1,419 | $96.91 | 6.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 14 | 31 | $341.00 | $93.00 | 27.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 162 | 286 | $65,816 | $29,125 | 44.3% |
About Dr. Abdullah Mubarak, MD
Dr. Abdullah Mubarak, MD is a Hepatology healthcare provider based in Tyler, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336109925.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Abdullah Mubarak, MD has received a total of $415,828 in payments from pharmaceutical and medical device companies, with $114,991 received in 2024. These payments were reported across 746 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($305,400).
As a Medicare-enrolled provider, Mubarak has provided services to 1,435 Medicare beneficiaries, totaling 2,057 services with total Medicare billing of $223,181. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hepatology
- Other Specialties Transplant Hepatology
- Location Tyler, TX
- Active Since 03/27/2006
- Last Updated 11/14/2019
- Taxonomy Code 207RI0008X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1336109925
Products in Payments
- Epclusa (Drug) $108,610
- MAVYRET (Drug) $54,683
- IQIRVO (Drug) $36,657
- Mavyret (Drug) $31,699
- REZDIFFRA (Drug) $19,061
- ZEPATIER (Drug) $13,240
- Livdelzi (Drug) $10,972
- Viekira (Drug) $8,227
- Vosevi (Drug) $6,913
- Vemlidy (Drug) $5,228
- FibroScan (Device) $5,120
- XIFAXAN (Drug) $760.65
- OCALIVA (Drug) $309.98
- LiverMultiScan (Device) $187.36
- RESMETIROM (Drug) $123.43
- Bylvay (Drug) $95.40
- Senza Spinal Cord Stimulation System (Device) $86.02
- UBRELVY (Drug) $57.64
- XENPOZYME (Biological) $36.10
- PreHevbrio (Drug) $29.13
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.